News & Events about Meiragtx Holdings Plc.
Globe Newswire
3 months ago
Results from the Phase 1/2 MGT009 study presented at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting set the stage for Phase 3 LUMEOS trial of botaretigene sparoparvovec in XLRP, which is actively dosing patientsLONDONandNEW YORK, Oct. 01, 2022 (GLOBE NEWSWIRE) -- MeiraGTx ...
Globe Newswire
4 months ago
--Manufacturing facilities built to accelerate development and delivery of advanced medicines to patients using state-of-the-art technology at scale, with quality appropriate for commercialization --Site reflects MeiraGTxs unique, end-to-end approach to gene therapy manufacturing to expedite ...
Globe Newswire
5 months ago
-- Recent Positive Topline Data from the Phase 1/2 Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) -- Financing Secured by Manufacturing Facilities Extends Cash Runway to Fourth Quarter 2024 LONDONandNEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE...
Ticker Report
9 months ago
Nisa Investment Advisors LLC acquired a new stake in MeiraGTx Holdings plc (NASDAQ:MGTX Get Rating) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,760 shares of the company’...
Dimensional Fund Advisors LP grew its position in shares of MeiraGTx Holdings plc (NASDAQ:MGTX Get Rating) by 27.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 238,590 shares of the companys stock after purchasing an ...